Nektar’s lead drug candidate shows promise in eczema trial, shares soar
 Nektar Therapeutics (NKTR.O), opens new tab said on Tuesday its lead drug candidate met the main goal of a mid-stage study testing the drug in eczema patients, sending its shares up by nearly 140%.
In the 393-patient global trial, experimental drug rezpegaldesleukin induced a statistically significant reduction in the severity of eczema, as measured on a widely used index.
Eczema, also known as atopic dermatitis, is a chronic skin condition that causes inflammation, redness and intense itching. An estimated 16.5 million adults in the U.S. suffer from it.
